Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 3;3(1):95-102.
doi: 10.3233/ADR-190109.

Mild Cognitive Impairment with a High Risk of Progression to Alzheimer's Disease Dementia (MCI-HR-AD): Effect of Souvenaid® Treatment on Cognition and 18F-FDG PET Scans

Maria Sagrario Manzano Palomo  1   2 , Belen Anaya Caravaca  3 , Maria Angeles Balsa Bretón  4 , Sergio Muñiz Castrillo  5 , Asuncion de la Morena Vicente  5 , Eduardo Castro Arce  6 , María Teresa Alves Prez  7
Affiliations

Mild Cognitive Impairment with a High Risk of Progression to Alzheimer's Disease Dementia (MCI-HR-AD): Effect of Souvenaid® Treatment on Cognition and 18F-FDG PET Scans

Maria Sagrario Manzano Palomo et al. J Alzheimers Dis Rep. .

Abstract

Background: Previous studies have shown that Souvenaid (medical food) can have benefits on memory, cognition, and function in early Alzheimer's disease (AD) and mild cognitive impairment (MCI).

Objective: Demonstrate that Souvenaid could improve or maintain cognition and has an effect on neurodegeneration biomarkers.

Methods: This cohort study was carried out from June 2015 through December 2016 in the Neurology Department, Infanta Cristina Hospital, Madrid, Spain. MCI-HR-AD were recruited using Petersen criteria, neuropsychology (NPS), and 18F-FDG PET scans to confirm the high risk of progression to dementia with one year of follow-up. Age, sex, vascular risk factors (VRF), and NPS values (Barcelona brief version) were analyzed. 18F-FDG PET scans were analyzed as a visual procedure. The study was approved by the Research Committee of ICH. Statistical analysis was made with SPSS 22.0 version.

Results: Subjects included 43 MCI patients (58.5% women; mean age 69.78±7.89): 17 receiving Souvenaid® treatment (ST), 24 receiving no treatment (WT) and 2 who withdrew. No differences were seen in VRF, only hypercholesterolemia, and were less prevalent in the ST group (p = 0.002). The rate of progression to dementia was 48.8% (no differences between groups, p = 0.654). A second round of 18F-FDG PET scans showed a significance worsening of glucose metabolism in WT (p = 0.001) versus ST, in which it was low (p = 0.050). For NPS testing, there was a significant worsening in memory performance in the WT group (p = 0.011) and a stabilization in ST (p = 0.083), as well as in executive functions and attention (worsening in WT, p = 0.014). For the Subjective Changing Scale (SCS), caregivers indicated a stabilization/improvement in ST (p = 0.017).

Conclusion: Souvenaid had a significant effect on several cognitive domains, and on SCS in patients with MCI-HR-AD. Its intervention had an impact on preservation on 18F-FDG PET scans.

Keywords: 18F-FDG PET scans; Alzheimer’s disease; Souvenaid®; mild cognitive impairment; neuropsychology.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to report.

Figures

Fig.1
Fig.1
Age at onset.
Fig.2
Fig.2
Cardiovascular risk factors. HTA, hypertension; DM, diabetes mellitus.
Fig.3
Fig.3
Total proteins in both groups.
Fig.4
Fig.4
Subjective Changing Scale (SCS): differences between groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Santana I, Farinha F, Freitas S, Rodrigues V, Carvalho Å (2015) [The epidemiology of dementia and Alzheimer disease in Portugal: Estimations of prevalence and treatment-costs] (in Portuguese). Med Port 28, 182–188. - PubMed
    1. Alzheimer’s Association (2015) 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 11, 332–384. - PubMed
    1. Prince M, Albanese E, Prina M (2014) World Alzheimer Report 2014. Dementia and risk reduction: An analysis of protective and modifiable factors. Alzheimer’s Disease International, London, UK.
    1. Chiang K, Koo EH (2014) Emerging therapeutics for Alzheimer’s disease. Ann Rev Pharmacol Toxicol 54, 381–405. - PubMed
    1. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ (2012) National Institute on Aging—Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8, 1–13. - PMC - PubMed

LinkOut - more resources